Real-World IBS Study Links IBS-Smart® and Trio-Smart® Testing to Lower Use of Selected Diagnostic Procedures and Lower Captured Diagnostic Costs
Gemelli Biotech today announced the publication of a real-world study in Frontiers in Gastroenterology evaluating healthcare resource utilization following IBS-Smart® and Trio-Smart® testing in adults with suspected irritable bowel syndrome (IBS). Gemelli Biotech funded the study and manufactures both tests.
Gemelli Biotech's Trio-Smart® 3-Gas Breath Test and IBS-Smart® Blood Test, Featured Across Multiple Research Presentations at DDW 2026
Gemelli Biotech announced today that its diagnostic technologies will be featured across multiple research presentations at DDW 2026, the world's premier gathering of gastrointestinal researchers and clinicians. These studies included the use of Trio-Smart®, a diagnostic 3-gas breath test developed and distributed by Gemelli Biotech that uniquely detects hydrogen sulfide, in addition to hydrogen and methane. Comprehensive 3-gas breath testing is exclusively available through Gemelli Biotech.
Gemelli Biotech's Innovative Trio-Smart® Breath Test Featured in Multiple Research Studies at DDW 2025
Gemelli Biotech and its technologies will be featured in several presentations at Digestive Disease Week® (DDW) 2025. These studies used Trio-Smart®, a diagnostic 3-gas breath test developed and distributed by Gemelli Biotech that uniquely detects hydrogen sulfide, in addition to hydrogen and methane.
New Breath Testing Data Using Gemelli Biotech’s Trio-Smart to Be Presented at DDW 2024
Gemelli Biotech and its technologies (Trio-Smart® and IBS-Smart®) will be featured in numerous presentations at DDW 2024.
